Dimebon's Action May Challenge Amyloid Theory

VIENNA — Dimebon—the abandoned Russian antihistamine that burst onto the Alzheimer's study scene with the only positive clinical data of 2008—may throw yet another curve ball into a research world that for years has focused almost entirely on the amyloid hypothesis.